menu
    • menu
    [{"orgOrder":0,"company":"Trogenix","sponsor":"Viralgen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"TGX-007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Trogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trogenix \/ Trogenix","highestDevelopmentStatusID":"4","companyTruncated":"Trogenix \/ Trogenix"},{"orgOrder":0,"company":"Trogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Trogenix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Trogenix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Trogenix \/ Undisclosed"},{"orgOrder":0,"company":"Trogenix","sponsor":"IQ Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Series A Financing","leadProduct":"TGX-007","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Trogenix","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Trogenix \/ IQ Capital","highestDevelopmentStatusID":"4","companyTruncated":"Trogenix \/ IQ Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Trogenix

    Menu

    Trogenix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGX-007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : IQ Capital

                            Deal Size : $95.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Trogenix Announces £70 million / $95 Million Series A Financing

                            Details : The Series A financing for TGX-007, a cell & gene therapy targeting cancer, aims to advance innovative treatment options.

                            Product Name : TGX-007

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            October 06, 2025

                            Lead Product(s) : TGX-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : IQ Capital

                            Deal Size : $95.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TGX-007

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Viralgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Viralgen Collaborates with Trogenix to Advance AAV Gene Therapy for Glioblastoma

                            Details : The collaboration aims to advance the clinical development of Trogenix's rAAV gene therapy, TGX-007, which is being evaluated for glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            May 06, 2025

                            Lead Product(s) : TGX-007

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Viralgen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Trogenix

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Trogenix Unveils Odyssey to Find 'One-nd-Done' Tumor Drugs

                            Details : Trogenix lead product candidate is being evaluated in preclinical studies for the treatment of patients with aggressive cancers including glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth